Patients with neovascular age-related macular degeneration who had treatment delayed due to the COVID-19 pandemic experienced worsening of their disease activity, according to a study.
In her presentation at the virtual Association for Research in Vision and Ophthalmology meeting, Lydia G. Stone, MBBS, said that lockdown in the United Kingdom led to significant delays in anti-VEGF injections and the prioritization of treatment of patients with the highest risk for vision loss.
“Previous research in Newcastle Eye Centre identified that during the first 4 weeks of the United Kingdom